Eugene Schneider - 02 Jan 2026 Form 4 Insider Report for IONIS PHARMACEUTICALS INC (IONS)

Role: EVP, Chf Clinical Develop Ofcr
Signature: By: Patrick R. O'Neil, attorney-in-fact For: Eugene Schneider
Issuer symbol: IONS
Transactions as of: 02 Jan 2026
Net transactions value: $0
Form type: 4
Filing time: 06 Jan 2026, 17:35:20 UTC
Previous filing: 04 Sep 2025
Next filing: 20 Jan 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Schneider Eugene	EVP, Chf Clinical Develop Ofcr	2855 GAZELLE COURT, CARLSBAD	By: Patrick R. O'Neil, attorney-in-fact For: Eugene Schneider	05 Jan 2026	0001838539

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	IONS	Non-Qualified Stock Option (right to buy)	Award	$0	+19,350		$0.000000	19,350	02 Jan 2026	Common Stock	19,350	$79.67	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Grant on 01/02/2026 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. Following this transaction, the option was exercisable as to 0 shares on 01/02/2026. 25% of the shares subject to the option will vest and become exercisable on 01/02/2027. Thereafter, the remaining shares subject to the option will vest and become exercisable in 36 equal monthly installments over the next 3 years.

Content

Grant on 01/02/2026 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. Following this transaction, the option was exercisable as to 0 shares on 01/02/2026. 25% of the shares subject to the option will vest and become exercisable on 01/02/2027. Thereafter, the remaining shares subject to the option will vest and become exercisable in 36 equal monthly installments over the next 3 years.